News

Key collaborations enable Abbott to increase its global presence and accessibility to patients who haven't used CGMs before.
The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. All other third-party marks are the property of their respective owners.
Abbott’s ABT diversified business portfolio appears to be well-positioned to drive continued momentum in 2025. The stock carries a Zacks Rank #2 (Buy) currently. Factors Driving ABT Shares Within ...
The American Diabetes Association's McCormick Place event was also a bit of a coming out party for North Chicago-based Abbott ...
Tandem Diabetes Care, Inc.’s TNDM t:slim X2 insulin pump with Control-IQ+ automated insulin delivery (AID) technology is now compatible with Abbott’s FreeStyle Libre 3 Plus continuous glucose ...
The latest version of Abbott's FreeStyle Libre continuous glucose monitor is now available via the NHS to eligible people with diabetes in the UK. Abbott's wearable FreeStyle Libre 3 device ...
Tandem Diabetes Care Announces t:slim X2™ Insulin Pump Compatibility with Abbott’s FreeStyle Libre® 3 Plus Sensor in the United States Business Wire Jun 20, 2025 ...
The strategy and product exec said Tandem aims to give patients options and reach more people who haven’t yet used insulin ...
Tandem Diabetes Care has announced its Tandem t:slim X2 insulin pump is now compatible with Abbott’s FreeStyle Libre 3 Plus ...